Why Is AMYLYX PHARMACEUTICA (AMLX) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 20, 2026 at 1:34 AM ET · reviewed against 18 wire stories
AMYLYX PHARMACEUTICA (AMLX) is drawing unusual attention today. Our newswire has captured 18 stories on AMLX across 10 sources in the last 36 hours, with AI sentiment reading mixed (avg 51/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
AMLX stock is moving higher today after the company priced an upsized $500 million public offering of 14.09 million common shares at $35.50 per share. The underwriters also received a 30-day option to purchase up to an additional 2.11 million shares. The offering is expected to close on or about August 21 and is intended to support the company’s growth and pipeline development. The move follows a recent surge in the stock, which has risen 70.3% over the last eight sessions.
What Happened
Amylyx Pharmaceuticals announced the pricing of its public offering, which significantly outsizes the $350 million originally reported in earlier coverage. The company’s shares are trading near their 52-week high of $35.39, with the offering price at $35.50. The offering includes a greenshoe option that could bring in up to an additional $75 million in capital. This follows a series of price target upgrades from analysts, including Guggenheim, Mizuho, and BofA, who raised their targets to $55, $42, and $39 respectively. The stock has been on a strong upward trajectory, driven by both capital-raising activity and analyst optimism.
What The Data Shows
Over the past eight trading sessions, AMLX has surged from $22.67 to $38.60, a gain of 70.3%. The stock printed two fresh 52-week highs and one 52-week low on August 20. Recent insider transactions include one sell transaction totaling $539,000. The stock remains unprofitable, with a trailing twelve-month revenue decline of 100.3% and an EPS of -1.43. Despite the strong price action, the company’s market cap of $2.4 billion reflects its pre-commercial status and ongoing losses.
What To Watch
The company’s public offering is expected to close on or about August 21. Investors should monitor the final transaction details and any follow-up commentary from analysts or executives. Coverage breadth remains elevated, with 18 stories from 10 sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AMLX · Aug 20 session (5-min) · +2.97% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 18 stories · 51/100 neutral
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
24d agoSeeking AlphaBEARISH 24General
Amylyx Pharmaceuticals prices upsized $500M public offering of common stock
Amylyx Pharmaceuticals (AMLX) announced the pricing of an upsized underwritten public offering of 14.09M shares of common stock at $35.50 per share. The company also granted underwriters a 30-day option to buy up to an additional 2.11M shares.
24d agoStockTitanBEARISH 26General
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
The offering covers 14.09 million shares at $35.50 each; underwriters can buy up to 2.11 million more, and closing is expected on or about Aug. 21.
24d agoMarketChameleonBEARISH 28General
Amylyx Eyes Major Capital Raise: $350 Million Public Offering Targets Growth and Pipeline Progress
Amylyx Pharmaceuticals has announced a proposed $350 million public offering of common stock, with the potential for an additional $52.5 million through underwriters’ options. The company aims to fund pre-commercial activities for avexitide, research and development, and general operations. Here’s what this move signals for AMLX’s future.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →